- Home
- GNFT vs CLLS Comparison
GNFT vs CLLS Comparison
Compare GNFT & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNFT
- CLLS
- Stock Information
- Founded
- GNFT 1999
- CLLS 1999
- Country
- GNFT France
- CLLS France
- Employees
- GNFT N/A
- CLLS N/A
- Industry
- GNFT Biotechnology: Biological Products (No Diagnostic Substances)
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- GNFT Health Care
- CLLS Health Care
- Exchange
- GNFT Nasdaq
- CLLS Nasdaq
- Market Cap
- GNFT 249.0M
- CLLS 240.2M
- IPO Year
- GNFT 2019
- CLLS 2007
- Fundamental
- Price
- GNFT $5.59
- CLLS $1.99
- Analyst Decision
- GNFT Strong Buy
- CLLS Buy
- Analyst Count
- GNFT 1
- CLLS 2
- Target Price
- GNFT $13.00
- CLLS $8.00
- AVG Volume (30 Days)
- GNFT 21.1K
- CLLS 23.1K
- Earning Date
- GNFT 09-19-2024
- CLLS 11-04-2024
- Dividend Yield
- GNFT N/A
- CLLS N/A
- EPS Growth
- GNFT N/A
- CLLS N/A
- EPS
- GNFT 0.47
- CLLS N/A
- Revenue
- GNFT $86,225,222.00
- CLLS $19,635,000.00
- Revenue This Year
- GNFT $155.44
- CLLS $271.02
- Revenue Next Year
- GNFT N/A
- CLLS $33.48
- P/E Ratio
- GNFT $11.74
- CLLS N/A
- Revenue Growth
- GNFT 175.45
- CLLS N/A
- 52 Week Low
- GNFT $2.97
- CLLS $0.96
- 52 Week High
- GNFT $6.05
- CLLS $3.77
- Technical
- Relative Strength Index (RSI)
- GNFT 62.71
- CLLS 38.05
- Support Level
- GNFT $5.12
- CLLS $1.95
- Resistance Level
- GNFT $5.84
- CLLS $2.06
- Average True Range (ATR)
- GNFT 0.32
- CLLS 0.10
- MACD
- GNFT 0.02
- CLLS -0.02
- Stochastic Oscillator
- GNFT 60.94
- CLLS 20.93
About GNFT GENFIT S.A.
Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of innovative medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.